Filgrastim is approved for several indications, including reduction of the incidence and
duration of chemotherapy-induced neutropenia and for stem cell mobilization. The filgrastim …

Granulopoiesis‐stimulating factors to prevent adverse effects in the treatment of solid tumors -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Aims This study estimated, for Saudi Arabia, the cost-efficiency of converting patients from
reference Neupogen and Neulastim to one of two filgrastim biosimilars (Nivestim, Zarzio); …

Simple Summary The most commonly reported adverse drug reactions (ADRs) related to
filgrastim (FIL) and pegfilgrastim (PEG-F) were obtained and analyzed from the European …

Pediatric acute myeloid leukemia (AML) generally occurs de novo. The treatment of AML
includes cytarabine (CYT) and other medications. The granulocyte-colony stimulating factor …

Advances in modern treatments, interdisciplinary research, and supportive care have led to
a decline in cancer mortality while improving remission rates, overall survival, and quality of …

PURPOSE Although multiple filgrastim biosimilars are now available in the United States, no
studies comparing clinical outcomes between products have been reported. This analysis …

Objective To identify risk factors for infection complications in patients with gastrointestinal
diffuse large B-cell lymphoma (GI-DLBCL) and nodal DLBCL (N-DLBCL) during treatment …

In the fast-evolving field of cancer treatment, the introduction of biosimilars has brought
about significant changes in the available therapeutic options. Biosimilars, which are …

Biosimilars are the medicines that are similar in structure and functions to biologics. They
are very much similar to their reference products—this means the product. The biosimilars …